ClinicalTrials.gg
RecruitingNCT06100744Updated Sep 1, 2026

A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab

A Phase 3 interventional study of Adalimumab and Risankizumab in Juvenile Psoriatic Arthritis, sponsored by AbbVie. Recruiting at 34 sites in 9 countries. Open to participants aged 5 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-09-01.

Sponsored by AbbVie · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2024; still recruiting 2 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
5 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 10 studies in Arthritis, Juvenile by AbbVie — 2 open to participants now, 3 under way, 2 of them phase 3. Arthritis, Juvenile · AbbVie.

Started
2024
the only one that year
Phase 3
4 of 10
2 open now
Registered
10th of 10
by date

Among the 10 studies in Arthritis, Juvenile by AbbVie, this one is the only one that started in 2024, is one of 4 in phase 3, and was the 10th registered.

Arthritis, Juvenile

365 studies on the registry are indexed under Arthritis, Juvenile; 101 are open to participants now.

Browse Arthritis, Juvenile studies →

Open to participants now

2 of the 10 studies in Arthritis, Juvenile by AbbVie are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 69 Arthritis, Juvenile studies recruiting now, 13 (19%) set no upper age limit and 50 (72%) stop at 75 or younger; 65 take children under 18; 11 take healthy volunteers.

This study: 5 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Arthritis, Juvenile by AbbVie, or all of them as a file.
02

Study summary

Psoriatic arthritis (PsA) is a type of arthritis that happens when the body's immune system attacks healthy cells and tissues causing joint pain, stiffness, and swelling. Symptoms can get worse and go away for periods of time. PsA that begins before a patient's 16th birthday is called juvenile PsA (jPsA).This study will evaluate how safe risankizumab is for the treatment of psoriatic arthritis and to assess change in disease symptoms.

Risankizumab is being studied for the treatment of jPsA and adalimumab is approved for the treatment of jPsA. Participants are placed in 1 of 2 groups, called treatment arms. Each group receives a different treatment. There is a 1 in 4 chance that participants will be assigned to receive adalimumab. Approximately 40 juvenile participants with jPsA will be enrolled at approximately 30 sites worldwide.

Participants will receive risankizumab and adalimumab as subcutaneous (SC) injections based on body weight. At the start of Period 1, participants are randomized to receive risankizumab or adalimumab for 24 weeks. Participants who respond to the study treatment received in Period 1, will continue to receive the same treatment in Period 2 for another 100 weeks. Those with worsening jPsA symptoms in Period 2 will be withdrawn from the study. Participants who receive adalimumab are followed for safety for 70 days after the last study treatment. Participants who receive risankizumab are followed for 140 days after the last study treatment.

There may be higher treatment burden for participants in this trial compared to their standard of care (due to study procedures). Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

03

Conditions studied

  • Juvenile Psoriatic Arthritis

Keywords

  • Juvenile Psoriatic Arthritis
  • Psoriatic Arthritis
  • Risankizumab
  • ABBV-066
  • Adalimumab
04

Who can participate

Ages eligible
5 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of juvenile psoriatic arthritis (jPsA) according to International League of Associations for Rheumatology criteria for at least 3 months prior to screening.
  • Active Disease in >= 3 joints at screening and at Baseline (swelling not due to deformity, or limitation of motion with pain, tenderness, or both) are eligible for inclusion in the study.
  • Have had an inadequate response (lack of efficacy after minimum 2-month duration of therapy at maximally tolerated dose), or intolerance to previous or current treatment with at least 1 of the following conventional synthetic disease-modifying antirheumatic drug (csDMARDs): methotrexate (MTX), sulfasalazine, leflunomide, or hydroxychloroquine.

Exclusion criteria

Exclusion Criteria:

  • Have any other disease, rheumatic disease (including systemic Juvenile idiopathic arthritis [JIA], rheumatoid factor-positive or rheumatoid factor-negative polyarticular JIA, extended oligoarticular JIA, persistent oligoarticular JIA, enthesitis-related arthritis, and undifferentiated JIA), or overlap syndrome.
  • Prior inadequate response to treatments in the anti-TNF or IL-23 inhibitor classes.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Risankizumab

    Participants will receive risankizumab for 24 weeks, in Period 1. Participants who respond to the study treatment received in Period 1, will continue to receive the same treatment in Period 2 for another 100 weeks. There will be a 140 day safety follow up after the treatment period.

    Drug: Risankizumab

  • Experimental
    Adalimumab

    Participants will receive adalimumab for 24 weeks, in Period 1. Participants who respond to the study treatment received in Period 1, will continue to receive the same treatment in Period 2 for another 100 weeks. There will be a 70 day safety follow up after the treatment period.

    Drug: Adalimumab

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants who Achieve >= 30% Improvement in Juvenile Idiopathic Arthritis American College of Rheumatology Response Criteria (JIA-ACR 30)

    The JIA-ACR 30 response is defined as a \>= 30% improvement of at least 3 or more of the 6 juvenile idiopathic arthritis core response variables (JIA-CRVs) without \>30% worsening in more than 1 of the remaining JIA-CRVs compared with Baseline. The 6 JIA-CRVs are: physician global assessment of disease activity (PhGA), global assessment of overall well being, no of joints with active arthritis, no of joints with limitation of motion high sensitivity C-reactive protein (hsCRP), and functional ability assessed by Childhood Health Assessment Questionnaire Disability Index (CHAQ-DI).

    Time frame: Up to 24 Weeks

  2. Number of Participants with Adverse Events (AEs)

    An AE is defined as any untoward medical occurrence in a patient or clinical investigation in which a participant is administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.

    Time frame: Up to Week 144

Secondary outcomes

  1. Percentage of Participants who Achieve >= 50% Improvement in Juvenile Idiopathic Arthritis American College of Rheumatology Response Criteria (JIA-ACR 50)

    The JIA-ACR 50 response is defined as a \>= 50% improvement of at least 3 or more of the 6 JIA-CRVs without \>50% worsening in more than 1 of the remaining JIA-CRVs compared with Baseline. The 6 JIA-CRVs are: PhGA, parent/patient global assessment of overall well being, no of joints with active arthritis, no of joints with limitation of motion hsCRP, and functional ability assessed using the disability index of the CHAQ-DI.

    Time frame: Up to 24 Weeks

  2. Percentage of Participants who Achieve >= 70% Improvement in Juvenile Idiopathic Arthritis American College of Rheumatology Response Criteria (JIA-ACR 70)

    The JIA-ACR 70 response is defined as a \>= 70% improvement of at least 3 or more of the 6 JIA-CRVs without \>70% worsening in more than 1 of the remaining JIA-CRVs compared with Baseline. The 6 JIA-CRVs are: PhGA, parent/patient global assessment of overall well being, no of joints with active arthritis, no of joints with limitation of motion hsCRP, and functional ability assessed using the disability index of the CHAQ-DI.

    Time frame: Up to 24 Weeks

  3. Percentage of Participants who Achieve >= 90% Improvement in Juvenile Idiopathic Arthritis American College of Rheumatology Response Criteria (JIA-ACR 90)

    The JIA-ACR 90 response is defined as a \>= 90% improvement of at least 3 or more of the 6 JIA-CRVs without \>90% worsening in more than 1 of the remaining JIA-CRVs compared with Baseline. The 6 JIA-CRVs are: PhGA, parent/patient global assessment of overall well being, no of joints with active arthritis, no of joints with limitation of motion hsCRP, and functional ability assessed using the disability index of the CHAQ-DI.

    Time frame: Up to 24 Weeks

  4. Change from Baseline in Juvenile Arthritis Disease Activity Score (JADAS)-10

    JADAS is a composite score of physician global assessment of disease activity, parent/patient global assessment of overall well-being, number of joints with active arthritis (swelling not due to deformity, or limitation of motion with pain, tenderness or both), and high sensitivity C-reactive protein (hsCRP). JADAS-10 is based on the count of any involved joint, up to a maximum of ten joints.

    Time frame: Up to Week 24

  5. Change from Baseline in JADAS-27

    JADAS is a composite score of physician global assessment of disease activity, parent/patient global assessment of overall well-being, number of joints with active arthritis (swelling not due to deformity, or limitation of motion with pain, tenderness or both), and hsCRP. JADAS-27 includes a count of the following joints: cervical spine, elbows, wrists, metacarpophalangeal joints (from first to third), and proximal interphalangeal joints, hips, knees, and ankles.

    Time frame: Up to Week 24

  6. Percentage of Participants with Achievement of Minimal Disease Activity (MDA)

    MDA is defined as JADAS-10 of \<= 6. JADAS-10 is based on the count of any involved joint, up to a maximum of ten joints.

    Time frame: Week 24

  7. Percentage of Participants with Inactive Disease

    Inactive disease is defined as JADAS-10 of \<= 2.7. JADAS-10 is based on the count of any involved joint, up to a maximum of ten joints.

    Time frame: Week 24

  8. Change from Baseline in Clinical Juvenile Arthritis Disease Activity Score (cJADAS)-10

    cJADAS is a composite score of physician global assessment of disease activity, parent/patient global assessment of overall well-being, and number of joints with active arthritis (swelling not due to deformity, or limitation of motion with pain, tenderness or both). JADAS-10 is based on the count of any involved joint, up to a maximum of ten joints.

    Time frame: Up to Week 24

  9. Change from Baseline in cJADAS-27

    cJADAS is a composite score of physician global assessment of disease activity, parent/patient global assessment of overall well-being, and number of joints with active arthritis (swelling not due to deformity, or limitation of motion with pain, tenderness or both). JADAS-27 includes a count of the following joints: cervical spine, elbows, wrists, metacarpophalangeal joints (from first to third), and proximal interphalangeal joints, hips, knees, and ankles.

    Time frame: Up to Week 24

  10. Change from Baseline in the Pain-Visual Analogue Scale (VAS)

    Participants assessed their pain using a Patient's Global Assessment Pain visual analogue scale (VAS). The range is 0 to 100 with no pain being indicated by 0 and severe pain by 100.

    Time frame: Week 24

  11. Percentage of Participants with Psoriasis (PsO) who Achieve Psoriasis Area Severity Index (PASI) 75 in Participants with at least 3% Body Surface Area (BSA) at Baseline

    The PASI is a measure of psoriasis severity. Four anatomic sites - head, upper extremities, trunk, and lower extremities - are assessed for erythema, induration and desquamation using a 5-point scale, with a lower score indicating more mild disease.

    Time frame: Up to Week 24

  12. Percentage of Participants with PsO who Achieve PASI 90 in Participants with at least 3% BSA at Baseline

    The PASI is a measure of psoriasis severity. Four anatomic sites - head, upper extremities, trunk, and lower extremities - are assessed for erythema, induration and desquamation using a 5-point scale, with a lower score indicating more mild disease.

    Time frame: Up to Week 24

  13. Percentage of Participants with PsO who Achieve Static Physician Global Assessment of Disease Activity (sPGA) of PsO of 'Clear' (0) or Almost Clear (1) in Participants with at least 3% BSA at Baseline

    The sPGA is a 5-point score ranging from 0 to 4, based on the physician's assessment of the average thickness, erythema, and scaling of all psoriatic lesions, with a lower score indicating less body coverage.

    Time frame: Up to Week 24

  14. Percentage of Participants with PsO who Achieve change from Baseline in Children's Dermatology Life Quality Index (CDLQI) in Participants with at least 3% BSA at Baseline

    The CDLQI is a 10-item questionnaire used to assess the impact of dermatologic disease symptoms and treatment on quality-of-life (QOL), with a higher score indicating greater impairment of QOL. The CDLQI has been validated for use in participants 4 to 16 years old.

    Time frame: Up to Week 24

07

Study locations

34 of 34 sites recruiting
  • Arkansas Children's Hospital /ID# 258776
    Little Rock, Arkansas 72202, United States
    Recruiting
    • Site Coordinator · Contact501-364-3686
  • Childrens National Medical Center /ID# 259284
    Washington D.C., District of Columbia 20010-2916, United States
    Recruiting
  • Joe Dimaggio Children's Hospital Hollywood /ID# 260634
    Hollywood, Florida 33021, United States
    Recruiting
    • Site Coordinator · Contact954-265-4466
  • All X Ray Diagnostic Services Corp /ID# 278523
    Miami, Florida 33126, United States
    Recruiting
  • Indiana University Health Riley Hospital for Children /ID# 259067
    Indianapolis, Indiana 46202, United States
    Recruiting
  • M Health Fairview University of Minnesota Medical Center - West Bank /ID# 260111
    Minneapolis, Minnesota 55454, United States
    Recruiting
  • Columbia University Medical Center /ID# 262587
    New York, New York 10032-3729, United States
    Recruiting
    • Site Coordinator · Contact212-305-4308
  • Boston Childrens Health Physicians /ID# 258061
    Valhalla, New York 10595, United States
    Recruiting
    • Site Coordinator · Contact914-504-0152
  • University of North Carolina - Children's Hospital /ID# 259286
    Chapel Hill, North Carolina 27514, United States
    Recruiting
    • Site Coordinator · Contact919-504-6650
  • MetroHealth Medical Center /ID# 262377
    Cleveland, Ohio 44109, United States
    Recruiting
  • Cleveland Clinic - Cleveland /ID# 276655
    Cleveland, Ohio 44195, United States
    Recruiting
  • Child Neurology Consultants of Austin /ID# 260562
    Austin, Texas 78757-7571, United States
    Recruiting
    • Site Coordinator · Contact512-494-4000
  • Monash Health - Monash Medical Centre - Clayton /ID# 260255
    Clayton, Victoria 3168, Australia
    Recruiting
  • Alberta Children's Hospital /ID# 257880
    Calgary, Alberta T3B 6A8, Canada
    Recruiting
  • British Columbia Children and Women's Hospital and Health Centre /ID# 257884
    Vancouver, British Columbia V6H 3N1, Canada
    Recruiting
  • Hospital for Sick Children /ID# 257879
    Toronto, Ontario M5G 1X8, Canada
    Recruiting
  • Chu Bordeaux - Hopital Pellegrin /ID# 258729
    Bordeaux, New Aquitaine 33076, France
    Recruiting
  • AP-HP - Hopital Bicetre /ID# 258728
    Le Kremlin-Bicêtre, Paris 94270, France
    Recruiting
  • Asklepios Klinik Sankt Augustin /ID# 259106
    Sankt Augustin, North Rhine-Westphalia 53757, Germany
    Recruiting
    • Site Coordinator · Contact+49-2241-249-240
  • Helios Klinikum Berlin - Buch /ID# 268803
    Berlin, 13125, Germany
    Recruiting
  • Hamburger Zentrum fuer Kinder- und Jugendrheumatologie /ID# 259104
    Hamburg, 22081, Germany
    Recruiting
  • Azienda Ospedaliero Universitaria Meyer /ID# 258587
    Florence, Firenze 50139, Italy
    Recruiting
  • ASST Centro Specialistico Ortopedico Traumatologico Gaetano Pini-CTO /ID# 276753
    Milan, Milano 20122, Italy
    Recruiting
  • Ospedale Pediatrico Bambino Gesu /ID# 258869
    Rome, Roma 00165, Italy
    Recruiting
  • Malopolskie Badania Kliniczne /ID# 258777
    Cracow, Lesser Poland Voivodeship 30-002, Poland
    Recruiting
  • Uniwersytecki Szpital Dzieciecy w Lublinie /ID# 258781
    Lublin, Lublin Voivodeship 20-093, Poland
    Recruiting
  • Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji im. prof. dr hab. med. /ID# 277050
    Warsaw, Masovian Voivodeship 02-637, Poland
    Recruiting
  • Centrum Zdrowia Dziecka i Rodziny im Jana Pawla II w Sosnowcu /ID# 277058
    Sosnowiec, Silesian Voivodeship 41-200, Poland
    Recruiting
  • SPZOZ Centralny Szpital Kliniczny Uniwersytetu Medycznego w Lodzi /ID# 258785
    Lodz, Łódź Voivodeship 91-738, Poland
    Recruiting
  • Hospital Sant Joan de Deu /ID# 257568
    Esplugues de Llobregat, Barcelona 08950, Spain
    Recruiting
  • Hospital Universitario y Politecnico La Fe /ID# 257567
    Valencia, 46026, Spain
    Recruiting
  • Sheffield Children's Hospital NHS Foundation Trust /ID# 258848
    Sheffield, England S10 2TH, United Kingdom
    Recruiting
  • University Hospitals Bristol and Weston NHS Foundation Trust /ID# 258847
    Bristol, BS2 8BJ, United Kingdom
    Recruiting
  • Alder Hey Children's NHS Foundation Trust /ID# 262770
    Liverpool, L12 2AP, United Kingdom
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.

Supporting information: Study protocol, Statistical analysis plan

Time frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/

Access criteria: To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2024 (actual). Primary completion is estimated for Sep 2026, 26 months after the start.

Of 36 phase 3 interventional studies under Arthritis, Juvenile, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 70. This study's planned 26 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 20, 2023
First posted
Oct 25, 2023
StartActual
Jul 8, 2024
Primary completionEst.
Sep 2026
CompletionEst.
Oct 2028
Last update
Sep 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06100744
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Oct 25, 2023
Start date
Jul 8, 2024
Primary completion
Sep 2026 (estimated)
Completion
Oct 2028 (estimated)
Last update
Sep 1, 2026

Study contacts

ABBVIE CALL CENTER
Contact
abbvieclinicaltrials@abbvie.com
844-663-3742
ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Adalimumab · Risankizumab

Start the discussion